A spiral microfluidic chip can enrich circulating tumor cells (CTCs) by steering cells into different paths as blood flows through a curved channel. The separation relies on physical forces and cell properties such as size—not a cancer-specific molecular label. The resulting fraction still needs downstream analysis: the chip enriches candidate cells but does not diagnose cancer.
Why circulating tumor cells need to be enriched
CTCs are cells shed into the bloodstream from a primary or metastatic tumor. They are rare among blood cells, which makes them difficult to isolate in sufficient numbers for characterization. Enrichment reduces the surrounding blood-cell background so candidate CTCs can be studied further.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Particles Separation in Microfluidic Devices | $50.99 | Buy on Amazon |
| 2 |
|
Optofluidic Devices and Applications | $46.90 | Buy on Amazon |
| 3 |
|
Microfluidics and Bio-MEMS: Devices and Applications | $144.25 | Buy on Amazon |
| 4 |
|
Enzyme Activity in Single Cells (Volume 628) (Methods in Enzymology, Volume 628) | $149.25 | Buy on Amazon |
| 5 |
|
Micro/Nano Devices for Blood Analysis | $50.53 | Buy on Amazon |
As an Amazon Associate I earn from qualifying purchases.
The phrase “spiral towards separation” is figurative. Cells do not actively seek a path; their positions shift as fluid forces act on them inside a curved microchannel. The 2013 Royal Society of Chemistry post introduced the approach and cited the paper “Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells”.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
How a slanted spiral chip separates cells
As a sample travels through the curved channel, Dean drag and inertial lift influence cells differently according to physical properties that include size. Those forces alter cells’ lateral positions. At the channel’s outlets, cells following different paths can be collected separately. The method can therefore enrich larger candidate tumor cells relative to smaller blood-cell background without relying on a particular surface marker for the initial separation.
#1 Best Overall
Marker independence can be useful when CTCs vary and a marker-based capture method might miss cells that lack the chosen marker. It does not mean a size-based chip captures every relevant CTC: cells with overlapping physical properties may not separate cleanly, and enrichment is not confirmation of malignancy.
What the reported performance figures mean
Results depend on the device design, sample, and workflow. These reported figures describe specific experiments, not guaranteed performance for every cancer or clinical blood sample.
| Study and context | Reported result | How to interpret it |
|---|---|---|
| Warkiani et al., Nature Protocols; published 17 December 2015, in the January 2016 issue | At least 85% recovery of spiked cells across tested cancer cell lines and 99.99% depletion of white blood cells in whole blood | Experimental protocol results; they do not establish recovery or depletion for every cancer type or patient sample. Read the protocol. |
| Warkiani et al., operating example for lysed blood using a three-layer multiplexed chip and two syringe pumps | 7.5 mL processed in 12.5 minutes | A stated workflow example for that configuration, not a universal throughput figure. Read the protocol. |
| Sarioglu et al., 2017 melanoma study | 83% average recovery in spiked melanoma samples; a 2-log white-cell reduction after one pass and 3-log after two | The recovery figure came from spiked healthy-donor blood experiments. The study also examined metastatic melanoma patient samples, but these figures are not patient-level diagnostic accuracy. Read the melanoma study. |
| Omrani et al., 2023, a different spiral microchannel design | Up to 92% CTC separation at approximately 1.7 mL/min | This result belongs to a distinct device configuration; it should not be attributed to the original slanted spiral chip. Read the study. |
What enrichment does—and does not—show
Recovery describes how many target cells are retained through a process; white-cell depletion describes how much of the white-cell background is removed. Neither measure by itself says whether the captured cells are malignant, whether a blood test can detect cancer reliably, or whether results improve patient outcomes. Those questions require downstream characterization and clinical validation.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →The melanoma study is an example of applying the approach to patient samples, alongside spiked-sample experiments. Its results do not establish the chip as a stand-alone diagnostic test or show that it can replace tissue biopsy or routine cancer monitoring.
How to compare spiral microfluidics with other CTC methods
A meaningful comparison needs the same sample type and clearly defined workflow. Consider these measures together rather than treating a single recovery percentage as a verdict:
- Target-cell recovery: what fraction of the intended cells is collected, and how was that measured?
- Residual blood cells: how much white-cell background remains after processing?
- Processing rate and time: which sample volume, chip design, and operating setup produced the figure?
- Downstream suitability: can the enriched cells be used for the intended characterization?
- Capture principle: does the method depend on a selected molecular marker, or on physical properties? Marker-based capture can be biased when cells are heterogeneous; label-free separation avoids dependence on a chosen marker but does not guarantee capture of every CTC.
What the technology means for patients
Spiral microfluidics is a research approach for preparing rare candidate cells for further study. The 2013 article framed it as a possible future way to track later-stage cancers, but that was prospective—not proof of clinical utility. The cited performance studies do not establish this chip as a replacement for repeated biopsies, a blood-based cancer diagnosis, or standard-of-care testing.
Quick Recap
Best Value
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
